California approves MT exam, 12/15
December 2015—American Medical Technologists announced the approval of the AMT Medical Technologist (MT) exam by the California Department of Public Health, Laboratory Field Services.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
CE-IVD mark for respiratory pathogen panel, 12/15
December 2015—Luminex received CE-IVD marking for its NxTAG Respiratory Pathogen Panel. The panel detects 21 clinically relevant viral and bacterial respiratory pathogens, including the atypical bacteria Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila.
NGS library preparation kit, 12/15
December 2015—New England Biolabs released its NEBNext Ultra II DNA Library Prep Kit for Illumina next-generation sequencing systems. The reagents for each step in the library preparation workflow have been reformulated to enable high-yield preparation—from a variety of sample types, including formalin-fixed, paraffin-embedded samples—of high-quality libraries, from 500 picograms to 1 microgram of input DNA.
NeoGenomics acquires Clarient, 12/15
December 2015—NeoGenomics has reached an agreement to acquire Clarient and its wholly owned subsidiary Clarient Diagnostic Services. Clarient, a unit of GE Healthcare’s Life Sciences business, is based in Houston and in Aliso Viejo, Calif., and has approximately 415 employees. Clarient had 2014 revenue of $127 million.
Tissue array, 12/15
December 2015—Leavitt Medical’s tissue array, BxChip, allows six needle core specimens to be placed in one block, enabling labs to reduce slide production by one-sixth. Labs that use BxChip find significant savings in the technical component.
Cell culture medium, 12/15
December 2015—Irvine Scientific released BalanCD Transfectory CHO, a cell culture medium for rapid, scalable production of recombinant proteins through transient transfection in CHO cells. The medium is chemically defined and animal component free and is designed to support sustained, high growth with increased transfection efficiency that can yield gram-scale protein expression.
Rheonix to expand commercialization efforts, 12/15
December 2015—Rheonix raised $28.6 million to further expand the company’s commercialization efforts for its molecular testing platforms, the Encompass MDx and Encompass Optimum.
Corning, BioCision form global distribution agreement, 12/15
December 2015—Corning Inc. and BioCision LLC announced an agreement in which Corning will become, on Jan. 1, 2016, the global distributor of popular BioCision products, including the innovative CoolCell cell cryopreservation systems, CoolBox ice-free sample preparation systems, CoolRack, CoolSink, and ThermalTray thermo-conductive sample tube and plate modules, TruCool ice pans and buckets, and CryoCeps cryogenic vial grippers.
Lab personnel management document, 12/15
December 2015—The Clinical and Laboratory Standards Institute published a new document titled “Laboratory Personnel Management (QMS16-Ed1).” This guideline describes the process for meeting the regulatory and accreditation requirements of personnel management in the laboratory environment.
OGT licenses SNP probe technology, 12/15
December 2015—Oxford Gene Technology has entered into a deal with Baylor Miraca Genetics Laboratories, licensing the use of OGT’s proprietary single nucleotide polymorphism array probe technology.